Oorsprong van het eerstegraads netwerk van Jean Bourgouin
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Kaneq Bioscience Ltd.
Kaneq Bioscience Ltd. BiotechnologyHealth Technology Kaneq Bioscience Ltd. operates as a biotechnology company focuses on developing treatments for type 2 diabetes. The firm develops a protein tyrosine phosphatase1B inhibitor for treating type 2 diabetes mellitus. The company was founded by Jean Bourgouin on October 19, 2012 and is headquartered in Montreal, Canada.
3
| Holding Company | Biotechnology | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Jean Bourgouin via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Fibrocor Therapeutics LP
Fibrocor Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety. | Miscellaneous Commercial Services | Director/Board Member | |
Clinical Research Institute of Montreal
Clinical Research Institute of Montreal Miscellaneous Commercial ServicesCommercial Services The Clinical Research Institute of Montreal engages in clinical research. | Miscellaneous Commercial Services | Chief Administrative Officer | |
HEC Montréal | College/University | Masters Business Admin | |
University of Montréal | College/University | Doctorate Degree | |
MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Kaneq Pharma, Inc. | Founder | ||
DEVONIAN HEALTH GROUP INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Québec Biotechnology Innovation Centre
Québec Biotechnology Innovation Centre BiotechnologyHealth Technology Québec Biotechnology Innovation Centre operates research and development center for biotechnology. It offers infrastructure, consulting, and funding services. The company was founded in 1995 and is headquartered in Laval, Canada. | Biotechnology | Director/Board Member | |
Génome Québec, Inc.
Génome Québec, Inc. Miscellaneous Commercial ServicesCommercial Services Génome Québec, Inc. develops genomics and DNA in Quebec. It helps to accelerate the discovery of new applications for genomics and DNA in strategic areas such as human health, forestry and the environment. The company was founded in 2000 and is headquartered in Montreal, Canada. | Miscellaneous Commercial Services | Director/Board Member | |
Apiary Therapeutics, Inc. | Director/Board Member | ||
Technologies Morphocell, Inc.
Technologies Morphocell, Inc. BiotechnologyHealth Technology Morphocell Technologies, Inc. aims to transform the treatment of severe liver diseases through cell therapy. The company is based in Laval, Canada. The Canadian company is developing stem cell-derived engineered liver tissues to replace liver functions and treat various forms of liver disease. Morphocell Technologies was founded in 2018 by Margaret Bywater Ekegard, Massimiliano Paganelli, and Raggi Claudia. Massimiliano Paganelli has been the CEO of the company since 2019. | Biotechnology | Director/Board Member | |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Biotechnology | Chairman | |
ACER THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
Delta TpX, Inc.
Delta TpX, Inc. Pharmaceuticals: OtherHealth Technology Delta TpX, Inc. develops oncology therapeutics. The American company was founded by Everett Stone, Aaron Schuchart, Cynthia Lavoie, David G. Lowe. David G. Lowe has been the CEO since incorporation. | Pharmaceuticals: Other | Founder | |
McGill University | College/University | Doctorate Degree | |
CCRM Enterprises Inc | President | ||
AllosteRx Capital Management (Canada), Inc. | Chief Executive Officer | ||
PROFOUND MEDICAL CORP. | Medical Specialties | Director/Board Member | |
TVM Life Science Management, Inc. | Investment Managers | Private Equity Investor | |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Rotman School of Management | College/University | Masters Business Admin | |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Biotechnology | Director/Board Member | |
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Pharmaceuticals: Major | Director/Board Member | |
Interface Biologics, Inc.
Interface Biologics, Inc. Information Technology ServicesTechnology Services Interface Biologics, Inc. operates as a commercial stage privately held company that develops transformative biomedical polymer technologies to improve the safety and effectiveness of medical devices. It provides technologies to medical device manufacturers and drug companies. The company was founded by Paul J. Santerre in December 2001 and is headquartered in Toronto, Canada. | Information Technology Services | Director/Board Member | |
University of Ottawa | College/University | Undergraduate Degree | |
Kanyr Pharma, Inc. | Director/Board Member |
Statistieken
Internationaal
Canada | 27 |
Verenigde Staten | 6 |
Sectoraal
Health Technology | 15 |
Consumer Services | 6 |
Commercial Services | 5 |
Finance | 3 |
Technology Services | 2 |
Operationeel
Director/Board Member | 19 |
President | 4 |
Founder | 3 |
Private Equity Investor | 2 |
Corporate Secretary | 2 |
Sterkste connecties
Insiders | |
---|---|
Cynthia Lavoie | 23 |
Daniel Bouthillier | 10 |
Philippe Tessier | 1 |
- Beurs
- Insiders
- Jean Bourgouin
- Bedrijfsconnecties